Lack of P-glycoprotein results in impairment of removal of beta-amyloid and increased intraparenchymal cerebral amyloid angiopathy after active immunization in a transgenic mouse model of Alzheimer's disease

Current Alzheimer Research

Volumn 14, Issue 6, 2017, Pages 656-667

  Brückmann, Sascha ^a   Brenn, Anja ^a   Grube, Markus ^a   Niedrig, Katharina ^a   Holtfreter, Silva ^a   Halbach, Oliver Von Bohlen Und ^a   Groschup, Martin ^b   Keller, Markus ^b   Vogelgesang, Silke ^a  

^a UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^b FEDERAL RESEARCH INSTITUTE FOR ANIMAL HEALTH   (Germany)

Author keywords

Active immunization; Alzheimer's disease; Amyloid angiopathy; Beta amyloid; Blood brain barrier; Clearance; Pglycoprotein

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; MULTIDRUG RESISTANCE PROTEIN; ABC TRANSPORTER SUBFAMILY B; ABCB1B PROTEIN, MOUSE; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); AMYLOID PRECURSOR PROTEIN; ANTIBODY; FREUND ADJUVANT; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 3; PEPTIDE FRAGMENT; PRESENILIN 1; PSEN1 PROTEIN, HUMAN;

ABSENCE; ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY; BRAIN HEMORRHAGE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOOD INTAKE; IMMUNE RESPONSE; LOCOMOTION; MALE; MICROGLIA; MOUSE; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; VASCULAR AMYLOIDOSIS; ANIMAL; BLEEDING; BLOOD; C57BL MOUSE; COMPLICATION; DEFICIENCY; DISEASE MODEL; EXPLORATORY BEHAVIOR; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIBODIES; ATP BINDING CASSETTE TRANSPORTER, SUB-FAMILY B; ATP-BINDING CASSETTE, SUB-FAMILY B, MEMBER 1; CEREBRAL AMYLOID ANGIOPATHY; DISEASE MODELS, ANIMAL; EXPLORATORY BEHAVIOR; FREUND'S ADJUVANT; HEMORRHAGE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; PRESENILIN-1;

EID: 85020305533     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205013666161201201227     Document Type: Article

References (66)

1. Kalaria RN, Maestre GE, Arizaga R, Friedland RP, Galasko D, Hall K, et al. Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol 7(9): 812-26 (2008).
2. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimers's diesease. Lancet 377(9770): 1019-31 (2011).
3. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297(5580): 353-6 (2002)
4. Holtzman DM, Morris JC, Goate A. Alzheimer's disease: the challenge of the second century. Sci Transl Med 3(77): 77sr1 (2011).
5. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC. Decreased Clearance of CNS Amyloid-β in Alzheimer’s Disease. Science 330(6012): 1774 (2010).
6. Shibata M, Yamada S, Kumar RS, Calero M, Bading J, Frangione B, et al. Clearance of Alzheimer’s amyloid-β1-40 peptide from brain by LDL receptor–related protein-1 at the blood-brain barrier. J Clin Invest 106(12): 1489-99 (2000).
7. Lam FC, Liu R, Lu P, Shapiro AB, Renoir J-M, Sharom FJ, et al. β-Amyloid efflux mediated by p-glycoprotein. J Neurochem 76: 1121-8 (2001).
8. Bartels AL, Kortekaas R, Bart J, Willemsen AT, de Klerk OL, de Vries JJ, et al. Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: A possible role in progressive neurodegeneration. Neurobiol Aging 30(11): 1818-24 (2009).
9. Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB, et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest 115(11): 3285-90 (2005).
10. Hartz AM, Miller DS, Bauer B. Restoring blood-brain barrier Pglycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer's disease. Mol Pharmacol 77(5): 715-23 (2010).
11. Kuhnke D, Jedlitschky G, Grube M, Krohn M, Jucker M, Mosyagin I, et al. MDR1-P-Glycoprotein (ABCB1) Mediates transport of Alzheimer’s amyloid-β peptides-implications for the mechanism of Aβ clearance at the blood-brain barrier. Brain Pathol 17(4): 347-53 (2007).
12. Vogelgesang S, Cascorbi I, Schroeder E, Pahnke J, Kroemer HK, Siegmund W, et al. Deposition of Alzheimer’s β-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 12(7): 535-41 (2002).
13. Vogelgesang S, Warzok RW, Cascorbi I, Kunert-Keil C, Schroeder E, Kroemer HK, et al. The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer’s disease. Curr Alzheimer Res 1(2): 121-5 (2004).
14. Campbell WA, Iskandar M-K, Reed, ML, Xia W. Endoproteolysis of presenilin in vitro: inhibition by gamma-secretase inhibitors. Biochemistry 41(10): 3372-9 (2002).
15. De Felice FG, Ferreira ST. Beta-amyloid production, aggregation, and clearance as targets for therapy in Alzheimer's disease. Cell Mol Neurobiol 22(5-6): 545-63 (2002).
16. Fahrenholz F, Postina R. Alpha-secretase activation--an approach to Alzheimer's disease therapy. Neurodegener Dis 3(4-5): 255-61 (2006).
17. Howell S, Nalbantoglu J, Crine P. Neutral endopeptidase can hydrolyze beta-amyloid(1-40) but shows no effect on beta-amyloid precursor protein metabolism. Peptides 16(4): 647-52 (1995).
18. Vassar R. Beta-secretase (BACE) as a drug target for Alzheimer's disease. Adv Drug Deliv Rev 54(12): 1589-602 (2002).
19. Spencer B, Masliah E. Immunotherapy for Alzheimer’s disease: past, present and future. Front Agning Neurosci 6: 114 (2014).
20. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, et al. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408: 979-82 (2000).
21. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-β attenuates Alzheimer disease-like pathology in the PDAPP mouse. Nature 400(6740): 173-7 (1999).
22. Dorostkar MM, Burgold S, Filser S, Barghorn S, Schmidt B, Anumala UR, et al. Immunotherapy alleviates amyloid-associated synaptic pathology in an Alzheimer's disease mouse model. Brain 137(Pt 12): 3319-26 (2014).
23. Siemers ER, Friedrich S, Dean RA, Gonzales CR, Farlow MR, Paul SM, et al. Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol 33(2): 67-73 (2010).
24. Bohrmann B, Baumann K, Benz J, Gerber F, Huber W, Knoflach F, et al. Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cellmediated removal of human amyloid-β. J Alzheimers Dis 28(1): 49-69 (2012).
25. Adolfsson O, Pihlgren M, Toni N, Varisco Y, Buccarello AL, Antoniello K, et al. An effector-reduced anti-β-amyloid (Aβ) antibody with unique Aβ binding properties promotes neuroprotection and glial engulfment of Aβ. J Neurosci 32(28): 9677-89 (2012).
26. Counts SE, Ray B, Mufson EJ, Perez SE, He B, Lahiri DK. Intravenous immunoglobulin (IVIG) treatment exerts antioxidant and neuropreservatory effects in preclinical models of Alzheimer's disease. J Clin Immunol 34(1): S80-5 (2014).
27. Lahiri DK, Ray B. Intravenous immunoglobulin treatment preserves and protects primary rat hippocampal neurons and primary human brain cultures against oxidative insults. Curr Alzheimer Res 11(7): 645-54 (2014).
28. Counts SE, Lahiri DK. Overview of immunotherapy in Alzheimer's disease (AD) and mechanisms of IVIG neuroprotection in preclinical models of AD. Curr Alzheimer Res 11(7): 623-5 (2014).
29. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al. Long-term effects of Aβ42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372(9634): 216-23 (2008).
30. Sakai K, Boche D, Carare R, Johnston D, Holmes C, Love S, et al. Aβ immunotherapy for Alzheimer's disease: effects on apoE and cerebral vasculopathy. Acta Neuropathol 128(6): 777-89 (2014).
31. Boche D, Zotova E, Weller RO, Love S, Neal JW, Pickering RM, et al. Consequence of Aβ immunization on the vasculature of human Alzheimer’s disease brain. Brain 131(Pt 12): 3299-310 (2008).
32. Bauer M, Karch R, Abrahim A, Wagner CC, Kletter K, Müller M, et al. Decreased blood-brain barrier P-glycoprotein function with aging. BMC Pharmacol 8(1): A48 (2008).
33. Rupp NJ, Wegenast-Braun BM, Radde R, Calhoun ME, Jucker M. Early onset amyloid lesions lead to severe neuritic abnormalities and local, but not global neuron loss in APPPS1 transgenic mice. Neurobiol Aging 32(12): 2324.e1-6 (2011).
34. Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L, et al. Aβ42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep 7(9): 940-6 (2006).
35. Schinkel AH, Mayer U, Wagenaar E, Mol CAAM, van Deemter L, Smit JJM, et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 94(8): 4028-33 (1997).
36. Chang B, Hawes NL, Hurd RE, Davisson MT, Nusinowitz S, Heckenlively JR. Retinal degeneration mutants in the mouse. Vision Res S 42(4): 517-25 (2002).
37. Pittler SJ, Baehr W. Identification of a nonsense mutation in the rod photoreceptor cGMP phosphodiesterase β-subunit gene of the rd mouse. Proc Natl Acad Sci USA 88(19): 8322-6 (1991).
38. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Meth 11(1): 47-60 (1984).
39. Brown RE, Wong AA. The influence of visual ability on learning and memory performance in 13 strains of mice. Learn Mem 14(3): 134-44 (2007).
40. Hall CS, Ballachey EL. A study of the rat's behavior in a field; a contribution to method in comparative psychology. Universtity of California publications in Psychology 6: 1-12 (1932).
41. Sha S, Xing X-N, Cao Y-P. Active immunotherapy facilitates Aβ plaque removal following through microglial activation without obvious T cells infiltrating the CNS. J. Neuroimmunol 274(1-2): 62-70 (2014).
42. Landgraf R, Wigger A. High vs low anxiety-related behavior rats: an animal model of extremes in trait anxiety. Behav Genet 32(5): 301-14 (2002).
43. Lipkind D, Sakov A, Kafkafi N, Elmer GI, Benjamini Y, Golani I. New replicable anxiety-related measures of wall vs. center behavior of mice in the open field. J Appl Physiol 97(1): 347-59 (2004).
44. Morrone CD, Liu M, Black SE, McLaurin J. Interaction between therapeutic interventions for Alzheimer’s disease and physiological Aβ clearance mechanisms. Front Aging Neurosci 7: 64 (2015).
45. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagen AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7(3): 280-92 (2011).
46. Jucker M. The benefits and limitations of animal models for translational research in neurodegenerative diseases. Nat Med 16(11): 1210-4 (2010).
47. Tanzi RE, Moir RD, Wagner SL. Clearance of Alzheimer's Abeta peptide: the many roads to perdition. Neuron 43(5): 605-8 (2004).
48. Hawkes CA, McLaurin J. Immunotherapy as treatment for Alzheimer's disease. Expert Rev Neurother 7(11): 1535-48 (2007).
49. DeMattos RB, Bales KR, Cummins DJ, Dodart J-C, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 98(15): 8850-5 (2001).
50. Mohajeri HM, Saini K, Schultz JG, Wollmer MA, Hock C, Nitsch RM. Passive immunization against beta-amyloid peptide protects central nervous system (CNS) neurons from increased vulnerability associated with an Alzheimer's disease-causing mutation. J Biol Chem 277(36): 33013-7 (2002).
51. Wilcock DM, Colton CA. Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice. CNS Neurol Disord Drug Targets 8(1): 50-64 (2009).
52. Wilcock DM, Roijani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, et al. Passive immunotherapy against Aβ in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 1: 24 (2004).
53. Vogelgesang S, Jedlitschky G, Brenn AW. The role of the ATPbinding cassette transporter p-glycoprotein in the transport of β-amyloid across the blood-brain barrier. Curr Pharm Des 17(26): 2778-86 (2011).
54. Brenn A, Grube M, Peters M, Fischer A, Jedlitschky G, Kroemer HK, et al. Beta-amyloid downregulates MDR1-P-glycoprotein (Abcb1) expression at the blood-brain barrier in mice. Int J Alzheimers Dis 2011: 690121 (2011).
55. Park R, Kook SY, Park JC, Mook-Jung I. Aβ1-42 reduces Pglycoprotein in the blood-brain barrier through RAGE-NF-κB signaling. Cell Death Dis 5(6): e1299 (2014).
56. Wang J, Lu R, Yang J, Li H, He Z, Jing N, et al. TRPC6 specifically interacts with APP to inhibit its cleavage by γ-secretase and reduce Aβ production. Nat Commun 6: 8876 (2015).
57. Wang J, Dickson DW, Trojanowski JQ, Lee VM. The levels of soluble versus insoluble brain Aβ distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol 158(2): 328-37 (1999).
58. McGeer PL, McGeer EG. Targeting microglia for the treatment of Alzheimer’s disease. Exp Opin Ther Targets 19(4): 1-10 (2014).
59. Bosch Neus M, Pugliese M, Andrade C, Gimeno-Bayón J, Mahy N, Rodriguez MJ. Amyloid-β immunotherapy reduces amyloid plaques and astroglial reaction in aged domestic dogs. Neurodegener Dis 15(1): 24-37 (2015).
60. Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol 14(4): 388-405 (2015).
61. Kooij G, Becker R, Koning JJ, Reijerkerk A, van Horssen J, van der Pol SM, et al. P-glycoprotein acts as an immunomodulator during neuroinflammation. PLoS One 4(12): e8212 (2009).
62. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73(24): 2061-70 (2009).
63. Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, et al. Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci USA 100(4): 2023-8 (2003).
64. Haslam IS, Jones K, Coleman T, Simmons NL. Rifampin and digoxin induction of MDR1 expression and function in human intestinal (T84) epithelial cells. Br J Pharmacol 154(1): 246-55 (2008).
65. Brenn A, Grube M, Jedlitschky G, Fischer A, Strohmeier B, Eiden M, et al. St. John's Wort reduces beta-amyloid accumulation in a double transgenic Alzheimer's disease mouse model-role of Pglycoprotein. Brain Pathol 24(1): 18-24 (2014).
66. Dinamarca MC, Cerpa W, Garrido J, Hancke JL, Inestrosa NC. Hyperforin prevents beta-amyloid neurotoxicity and spatial memory impairments by disaggregation of Alzheimer's amyloid-betadeposits. Mol Psychiatry 11: 32-1048 (2006).